NCT04902807 - Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation | Biotech Hunter

Enrollment

500

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

May 14, 2025

Study Completion Date

June 30, 2026

Conditions

Autoimmune Lymphoproliferative SyndromeAutoimmune CytopeniaAutoimmune DiseasesAutoimmune AnemiaAutoimmune ThrombocytopeniaAutoimmune HepatitisAutoimmune DiabetesAutoimmune Rheumatologic DiseaseSystemic Lupus ErythematosusJuvenile Idiopathic ArthritisHemophagocytic LymphohistiocytosesEBV LymphoproliferationRAS-Associated Autoimmune Leucoproliferative DiseasePrimary ImmunodeficiencyAPECEDIPEXBENTAEnteropathy, AutoimmuneCombined ImmunodeficiencyIBD

Interventions

BIOLOGICAL

Collection of samples

Blood, Urine and Stool samples will be collected from the participants.

Trial Locations (1)

Unknown

RECRUITING

hôpital Necker Enfants Malades, Paris

All Listed Sponsors

lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV